Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance [J].
Kim, Hyungjoo ;
Choi, Je-Min ;
Lee, Kyung-min .
BIOMEDICINES, 2022, 10 (05)
[42]   Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple-Negative Breast Cancer [J].
Wang, Xinran ;
Wang, Lingxia ;
Liu, Yueping .
THORACIC CANCER, 2025, 16 (09)
[43]   Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer [J].
Kim, Han Gyeol ;
Kang, So Young ;
Kim, Kyoung - Mee ;
Kim, Ji - Yeon ;
Park, Yeon Hee ;
Ahn, Jin Seok ;
Im, Young - Hyuck ;
Lim, Yoojoo ;
Song, Sanghoon ;
Paeng, Kyunghyun ;
Cho, Eun Yoon .
ANTICANCER RESEARCH, 2025, 45 (06) :2575-2586
[44]   Therapeutic potential of triple-negative breast cancer immune checkpoint blockers A 21-year bibliometric analysis [J].
Sun, Zhongli ;
Liu, Cun ;
Yao, Yan ;
Gao, Chundi ;
Li, Huayao ;
Wang, Longyun ;
Li, Ye ;
Sun, Changgang .
MEDICINE, 2025, 104 (10)
[45]   Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence [J].
Farshbafnadi, Melina ;
Khoshbin, Amin Pastaki ;
Rezaei, Nima .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 98
[46]   A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer [J].
Liu, Jingyi ;
Ling, Yuwei ;
Su, Ning ;
Li, Yan ;
Tian, Siyuan ;
Hou, Bingxin ;
Luo, Shanquan ;
Zhao, Lina ;
Shi, Mei .
TRANSLATIONAL CANCER RESEARCH, 2022, 11 (01) :181-+
[47]   Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis [J].
Sternschuss, Michal ;
Yerushalmi, Rinat ;
Saleh, Ramy R. ;
Amir, Eitan ;
Goldvaser, Hadar .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (11) :3369-3379
[48]   Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer [J].
Xu, Zhaowei ;
Liu, Shuyan ;
Feng, Chun ;
Xu, Fuyi ;
Kong, Demin ;
Mi, Jia ;
Yang, Chunhua ;
Zhang, Guilong ;
Wei, Pengfei ;
Orgil, Buyan-Ochir ;
Bergquist, Jonas ;
Tian, Geng .
CELL DEATH DISCOVERY, 2022, 8 (01)
[49]   The role of metabolic reprogramming in immune escape of triple-negative breast cancer [J].
Bao, Ruochen ;
Qu, Hongtao ;
Li, Baifeng ;
Cheng, Kai ;
Miao, Yandong ;
Wang, Jiangtao .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[50]   Angiogenesis and immune microenvironment in triple-negative breast cancer: Targeted therapy [J].
Zhang, Ying ;
Yang, Hao ;
Jiang, Yanhong ;
Jiang, Yijing ;
Mao, Renfang .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2025, 1871 (06)